Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration

NCT06141460 is registered in ClinicalTrials.gov with Shanghai Refreshgene Technology Co., Ltd. as lead sponsor.

NCT NCT06141460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06141460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Lead sponsor
Shanghai Refreshgene Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 12, 2023
Completion date
December 31, 2030
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration